Several computational methods have been developed to predict amyloid propensity of a protein or peptide. These bioinformatics tools are time- and cost-saving alternatives to expensive and laborious experimental methods which are used to confirm self-aggregation of a protein. Computational approaches not only allow preselection of reliable candidates for amyloids but, most importantly, are capable of a thorough and informative analysis of a protein, indicating the sequence determinants of protein aggregation, identifying the potential causal mutations and likely mechanisms. Bioinformatics modeling applies several different approaches, which most typically include physicochemical or structure-based modeling, machine learning, or statistics based modeling. Bioinformatics methods typically use the amino acid sequence of a protein as an input, some also include additional information, for example, an available structure. This chapter describes the methods currently used to computationally predict amyloid propensity of a protein or peptide. Since the accuracy of bioinformatics methods may be highly dependent on reference data used to develop and evaluate the predictors, we also briefly present the main databases of amyloids used by the authors of bioinformatics tools.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-0716-1546-1_1 | DOI Listing |
Pediatr Infect Dis J
January 2025
Public Health Secretariat, Department of Health, Generalitat de Catalunya, Barcelona, Spain.
Background: In Catalonia, infants <6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyze nirsevimab's effectiveness in hospital-related outcomes of the seasonal cohort (born during the RSV epidemic from October to January 2024) and compared them with the catch-up cohort (born from April to September 2023).
Methods: Retrospective cohort study of all infants born between October 1, 2023, and January 21, 2024, according to their immunization with nirsevimab (immunized and nonimmunized).
Neurology
February 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Background And Objectives: Chronic kidney disease (CKD) is known to be associated with increased plasma phosphorylated tau217 (p-tau217) concentrations, potentially confounding the utility of plasma p-tau217 measurements as a marker of amyloid pathology in individuals with suspected Alzheimer disease (AD). In this study, we quantitatively investigate the relationship of plasma p-tau217 concentrations vs estimated glomerular filtration rate (eGFR) in individuals with CKD with and without amyloid pathology.
Methods: This was a retrospective examination of data from 2 observational cohorts from either the Mayo Clinic Study of Aging or the Alzheimer's Disease Research Center cohorts.
Neurol Neuroimmunol Neuroinflamm
March 2025
MeLis Institute, SynatAc Team, Inserm U1314/ UMR CNRS5284, France.
Background And Objectives: Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression of the Yo-onconeural antigens. They are infiltrated by an unusual proportion of B cells. We investigated whether these features were also observed in patients with PNS and anti-Ri antibodies (Ri-PNS).
View Article and Find Full Text PDFEur Heart J Cardiovasc Imaging
January 2025
National Heart Center Singapore, Singapore, Singapore.
Aims: To identify differences in CT-derived perivascular (PVAT) and epicardial adipose tissue (EAT) characteristics that may indicate inflammatory status differences between post-treatment acute myocardial infarction (AMI) and stable coronary artery disease (CAD) patients.
Methods And Results: A cohort of 205 post-AMI patients (age 59.8±9.
J Dev Behav Pediatr
January 2025
Department of Pediatrics and Norton Children's Research Institute, School of Medicine, University of Louisville, Louisville, KY.
Objective: Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by social communication differences and restricted interests. One proposed biologic mechanism underlying ASD is oxidative stress, leading to the clinical use of glutathione based on anecdotal reports of improved behavior in autistic children. In this pilot study, we tested this observation using a randomized clinical trial format to collect preliminary data on glutathione safety and efficacy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!